BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 23828240)

  • 1. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.
    Lu-Emerson C; Snuderl M; Kirkpatrick ND; Goveia J; Davidson C; Huang Y; Riedemann L; Taylor J; Ivy P; Duda DG; Ancukiewicz M; Plotkin SR; Chi AS; Gerstner ER; Eichler AF; Dietrich J; Stemmer-Rachamimov AO; Batchelor TT; Jain RK
    Neuro Oncol; 2013 Aug; 15(8):1079-87. PubMed ID: 23828240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.
    Steidl E; Pilatus U; Hattingen E; Steinbach JP; Zanella F; Ronellenfitsch MW; Bähr O
    PLoS One; 2016; 11(12):e0168113. PubMed ID: 28033329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure.
    Lima L; Oliveira D; Tavares A; Amaro T; Cruz R; Oliveira MJ; Ferreira JA; Santos L
    Urol Oncol; 2014 May; 32(4):449-57. PubMed ID: 24252833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
    Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
    Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
    Lin P; Jiang H; Zhao YJ; Pang JS; Liao W; He Y; Lin ZY; Yang H
    Int Immunopharmacol; 2021 Aug; 97():107826. PubMed ID: 34091114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma.
    Levin VA; Mendelssohn ND; Chan J; Stovall MC; Peak SJ; Yee JL; Hui RL; Chen DM
    J Neurooncol; 2015 Mar; 122(1):145-50. PubMed ID: 25575937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.
    Morisse MC; Etienne-Selloum N; Bello-Roufai D; Blonski M; Taillandier L; Lorgis V; Noël G; Ahle G; Durán-Peña A; Boone M; Chauffert B
    J Neurooncol; 2019 Sep; 144(2):419-426. PubMed ID: 31325146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
    Toh CH; Liau CT; Wei KC; Castillo M
    J Neurooncol; 2019 Mar; 142(1):149-159. PubMed ID: 30535596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
    Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
    Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy.
    Hattingen E; Bähr O; Rieger J; Blasel S; Steinbach J; Pilatus U
    PLoS One; 2013; 8(3):e56439. PubMed ID: 23520454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of arterial hypertension as a predictive marker for bevacizumab efficacy in recurrent glioblastoma - a prospective analysis.
    Wagner CC; Held U; Kofmehl R; Battegay E; Zimmerli L; Hofer S
    Acta Oncol; 2014 Apr; 53(4):572-5. PubMed ID: 24219539
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
    Redjal N; Reinshagen C; Le A; Walcott BP; McDonnell E; Dietrich J; Nahed BV
    J Neurooncol; 2016 May; 127(3):505-14. PubMed ID: 26830093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of discontinuing bevacizumab prior to malignant glioma progression.
    Sherman WJ; Raizer JJ; Grimm SA
    J Neurooncol; 2013 Jan; 111(1):87-9. PubMed ID: 23065093
    [No Abstract]   [Full Text] [Related]  

  • 15. Continuous daily sunitinib for recurrent glioblastoma.
    Kreisl TN; Smith P; Sul J; Salgado C; Iwamoto FM; Shih JH; Fine HA
    J Neurooncol; 2013 Jan; 111(1):41-8. PubMed ID: 23086433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated microenvironment-associated genomic profiles identify LRRC15 mediating recurrent glioblastoma-associated macrophages infiltration.
    Tang H; Liu W; Xu Z; Zhao J; Wang W; Yu Z; Wei M
    J Cell Mol Med; 2021 Jun; 25(12):5534-5546. PubMed ID: 33960636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
    Vymazal J; Wong ET
    Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab.
    Tamura R; Tanaka T; Ohara K; Miyake K; Morimoto Y; Yamamoto Y; Kanai R; Akasaki Y; Murayama Y; Tamiya T; Yoshida K; Sasaki H
    Cancer Sci; 2019 Feb; 110(2):499-508. PubMed ID: 30467920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.
    Lombardi G; Zustovich F; Farina P; Fiduccia P; Della Puppa A; Polo V; Bertorelle R; Gardiman MP; Banzato A; Ciccarino P; Denaro L; Zagonel V
    Anticancer Drugs; 2013 Jan; 24(1):90-7. PubMed ID: 23075631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.
    Kickingereder P; Götz M; Muschelli J; Wick A; Neuberger U; Shinohara RT; Sill M; Nowosielski M; Schlemmer HP; Radbruch A; Wick W; Bendszus M; Maier-Hein KH; Bonekamp D
    Clin Cancer Res; 2016 Dec; 22(23):5765-5771. PubMed ID: 27803067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.